Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, today ...

NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskel ...

Instylla, Inc., a developer of resorbable embolics for peripheral vascular embolization, announced the completion of the ...

BOULDER, Colo., June 25, 2025 /PRNewswire/ -- Embolization, Inc., has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Nitinol Enhanced Device (NED). The NED is a ...

The treatment of a subdural hematoma received a major boost with three new randomized controlled trials all showing large and significant benefits of a new embolization process done as an endovascular ...

PHOENIX -- For chronic or subacute subdural hematoma, embolization of the middle meningeal artery (MMA) reduced recurrence, three randomized trials showed. Two trials with the Onyx liquid embolic ...

Patients receiving standard treatment for chronic subdural hematoma have a high risk of treatment failure. The effect of adjunctive middle meningeal artery embolization on the risk of treatment ...